Fiscal Year Ended March 2012 Results Briefing

from the beginning

Fiscal Year Ended March 2012 Results Briefing

presenter :

Junichi Yoshii
President & Representative Director

Fiscal Year Ended March 2012 Overview of Results

• Fiscal Year Ended March 2012: Overview of Results-1

• Fiscal Year Ended March 2012: Overview of Results-2

Medium-Term Management Plan (FY2009-2011) Overview

• Medium-Term Management Plan (FY2009-2011) Overview-1

• Medium-Term Management Plan (FY2009-2011) Overview-2

• Medium-Term Management Plan (FY2009-2011) Overview-3

• Medium-Term Management Plan (FY2009-2011) Overview-4

Plans for the Fiscal Year Ending March 2013

• Plans for the Fiscal Year Ending March 2013

• Cost of Sales Ratio for FY Ending March 2013

Use of Cash Flows

• Capital Investments and Depreciation

• Return to shareholders (Dividend)

• The New System

FY2011 and FY2012 Sales Measures

presenter :

Norihiro Tanaka
Managing Director &
Chief Director of Medicine Sales

• MR Activities: Number of Interviews with Physicians for all MRs

• MR Activities: Briefings for Dispensaries

• MR Activities: Kampo Medicine Seminars

• Kampo Formulations for Prescription: Growth

• Kampo Formulations for Prescription: Latest Growth

Research Progress

• Use of Evidence

• Digestive Disease Week (DDW) in the United States: Number of Presentations on Kampo

• DKT Forum Progress

• Drug Fostering Clinical Study (DB-RCT) Progress-1

• Drug Fostering Clinical Study (DB-RCT) Progress-2

• Scheduled New Clinical Research

• Conduct Kampo Oncology seminars for cancer specialists

• DKT Forum: Presentations in Japan Part 1

• Drug Fostering Events & Participating Physicians

• Website for Physicians Kampo Square Membership

• Website for Physicians Kampo Square: New Membership

Crude Drug

presenter :

Tsuyoshi Iwasawa
Executive Officer
Chief Director of Crude Drug

Crude Drug Procurement Flow in China

• Basic Flow of Crude Drug Procurement (China)-1

• Basic Flow of Crude Drug Procurement (China)-2

Steep Rise in Crude Drug Prices

• Reasons for the Steep Rise in Crude Drug Prices in China

• Context for the Steep Rise in Crude Drug Prices (China)

• Production Area Purchase Price for Ginseng

• Production Area Purchase Price for Chinese Peony

• Purchase Price for All Crude Drug Produced in China

Impact on B/S and P/L

• Impact on B/S and P/L

• Impact and Timing of “Rising Unit Cost of Crude Drug

Future Measures

• Measures to Develop Stable Crude Drug Procurement (Quantity, Quality, Price)

• Definition of “Cultivated Land under Own Management

• Effect of Expanding Cultivated Land under Own Management

Reference Materials

• Net Sales of Kampo Formulation for Prescription (129 Prescriptions)

• Top 10 Prescription Kampo Preparation in Terms of Net Sales